Related Experiment Video

Updated: Aug 12, 2026

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine
05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Ventilator-associated pneumonia monitoring according to the INICC project at one centre

Wiesława Duszyńska1, Victor D Rosenthal, Barbara Dragan

  • 1Chair and Department of Anaesthesiology and Intensive Therapy, Wrocław Medical University, Poland. w.duszynska@onet.eu.

Anaesthesiology Intensive Therapy
|March 10, 2015
PubMed

Insights

Ventilator-associated pneumonia (VAP) surveillance in ICUs shows persistent high incidence despite lower rates than previous reports. Key pathogens include Acinetobacter baumannii and Pseudomonas aeruginosa, necessitating further investigation and intervention.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Hospital Epidemiology

Background:

  • Ventilator-associated pneumonia (VAP) is a significant complication for critically ill, mechanically ventilated patients.
  • Effective surveillance programs are crucial for monitoring and controlling VAP incidence in intensive care units (ICUs).

Purpose of the Study:

  • To evaluate the utility of the International Nosocomial Infection Control Consortium (INICC) program for VAP surveillance.
  • To estimate VAP incidence, aetiology, and associated mortality in a hospital setting.

Main Methods:

  • Prospective study conducted over 2.5 years in a 20-bed ICU.
  • Monitored device utilization ratios, VAP frequency (density and incidence), and causative pathogens.
  • Calculated VAP rates per 1000 ventilator days.

Main Results:

  • VAP diagnosed in 93 of 1097 patients; 30% mortality.
  • VAP incidence index of 8.47 per 100 ICU admissions.
  • Primary pathogens: Acinetobacter baumannii (45%) and Pseudomonas aeruginosa (17%).
  • VAP rates per 1000 ventilator days: 11.15 (2012), 9.34 (2013), 10.23 (2014).

Conclusions:

  • VAP incidence was lower than INICC reports but tenfold higher than NHSN/CDC data.
  • Consistent VAP levels over 2.5 years indicate a need for root cause analysis.
  • Targeted interventions are required to reduce the persistent VAP burden.
Abstract

More Related Videos

Non-Intubated Video-Assisted Thoracoscopic Surgery05:39

Non-Intubated Video-Assisted Thoracoscopic Surgery

Published on: May 26, 2023

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit05:56

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit

Published on: September 6, 2024

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.6K
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.2K
Mechanical Ventilation II: Invasive Ventilation01:23

Mechanical Ventilation II: Invasive Ventilation

Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
1.2K
Mechanical Ventilation III: Noninvasive Ventilation01:23

Mechanical Ventilation III: Noninvasive Ventilation

Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
929